Clinical and immunological characteristics of sarcomas patients with clonogenic tumors

• Published in: Immunobiology (1979) 2021-07, Vol.226 (4), p.152094-152094, Article 152094
• Main Authors: Avdonkina, N.A., Danilova, A.B., Nekhaeva, T.L., Prosekina, E.A., Emelyanova, N.V., Novik, A.V., Girdyuk, D.V., Gafton, G.I., Baldueva, I.A.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Bone Neoplasms - immunology; Bone Neoplasms - mortality; Bone Neoplasms - pathology; Bone Neoplasms - therapy; Cancer Vaccines - administration & dosage; Child; Clonogenic potential; Dendritic Cells - immunology; Female; Humans; Immune response; Immunotherapy; Intra-tumoral heterogeneity; Killer Cells, Natural - immunology; Male; Metastatic sarcoma; Middle Aged; Neutrophil to lymphocyte ratio; Prognosis; Sarcoma - immunology; Sarcoma - mortality; Sarcoma - pathology; Sarcoma - therapy; Soft Tissue Neoplasms - immunology; Soft Tissue Neoplasms - mortality; Soft Tissue Neoplasms - pathology; Soft Tissue Neoplasms - therapy; T-Lymphocytes, Cytotoxic - immunology; Young Adult
• ISSN: 0171-2985; 1878-3279
• DOI: 10.1016/j.imbio.2021.152094

Tumorigenesis is related to the generation of heterogeneous tumor cell population, which is the result of genetic and epigenetic alterations followed by clonal selections and subsequent expansion. In basic studies genetic, histological and morphological diversity of different clones within a patient's neoplasm and specifics of their interrelation with patient's immune system are investigated mostly on the models of tumors of epithelial origin. Mesenchymal tumors such as soft tissue and bone-derived sarcomas (STBS) have been poorly studied in this regard. The molecular genetic methods used to examine intratumoral heterogeneity do not currently provide insight into which portion of the identified subclones are able to grow autonomously. Limiting dilution cloning demonstrates the existence of self-regulating tumor cells in the population and can serve as an independent prognostic predictor of poor prognosis. Intratumoral heterogeneity results not only in differences in growth dynamics, gene expression, and phenotypic markers, but also in the resistance to treatment, especially immunotherapy, thus causing tumor eluding immune escape. The changes that accompany this process can be affected by the cellular immune system, resulting in an imbalance between populations. The variations in the population composition of immune system cells are now widely debated as a predictor of response to immunotherapy, which is of obvious interest for sarcomas, where the effectiveness of chemotherapy is low and the prognosis is unfavorable, especially in case of metastatic disease development. The search for new predictive markers of disease prognosis and treatment efficacy is an important task, to which this study is focused. Our results demonstrate that clonogenic tumor characteristics such as clonogenic potential is independent predictor of unfavorable prognosis in cases of cancer and correlate with the clinical characteristics of the tumor such as overall survival (OS) and progression free survival (PFS). It was found that patients with clonogenic sarcomas had a lower content of activated cytotoxic T-lymphocytes (CTL) with the CD3+CD8+HLA-DR+ phenotype and an increased number of natural NK killers (p